glp-1 brain inflammation glp 1 Study identifies gut-brain-immune network influencing effectiveness of agonists Glucagon-like peptide-1 medicines in neurological – Glucagon-like peptide (GLP)-1 and GLP-2

Brown discoloration specifically suggests advanced oxidation or contamination and means the vial should be discarded regardless of timeline

They should not be used by: People with a history of pancreatitis (inflammation of the pancreas) Anyone with a personal or family history of medullary thyroid cancer (a rare type of thyroid cancer) People with multiple endocrine neoplasia type 2 (MEN 2, a rare inherited condition that raises the risk of certain hormone-related tumors, including thyroid cancer) Women who are pregnant or breastfeeding People with severe stomach or bowel problems, such as gastroparesis (slow stomach emptying that causes nausea, fullness, or vomiting) or inflammatory bowel disease (chronic inflammation of the digestive tract, such as Crohns disease or ulcerative colitis) Those with severe kidney problems, especially with certain types of GLP-1 medicines, such as exenatide Anyone with allergies to GLP-1 medications or who has had a severe reaction to them Use in children is limited to certain GLP-1 medicines approved for adolescents with obesity

10.3892/or.2016.5002 Oncol Rep

Hypertension-linked pathophysiological alterations in the gut

(2008) 49(Suppl 8):425